Clearside – $36 Million Public Offering

Reston – January 3, 2017 – Cooley advised Clearside Biomedical on its $36 million public offering of 4,000,000 shares of common stock.

Clearside, which trades on the NASDAQ Global Market under the symbol “CLSD,” is a late-stage clinical biopharmaceutical company developing innovative drug therapies to treat blinding diseases of the eye.

In addition to representing Clearside on the offering, Cooley has served as intellectual property counsel to the company since 2012. Earlier this year, Cooley also advised Clearside on its $50 million IPO.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brian Leaf  Partner Reston
Brent Siler  Senior Counsel Washington, DC, Reston
Darren DeStefano  Partner Reston
Mark Ballantyne  Partner Reston
Katie Kazem  Partner Reston
Michael Tuscan  Partner Washington, DC
Erik Milch  Partner Reston
Jeremy Binstock  Associate Reston
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Mark Windfeld-Hansen  Senior Counsel Palo Alto
Francis Wheeler  Partner Colorado